Affinity Asset Advisors »

First Tracks Biotherapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of First Tracks Biotherapeutics (TRAX) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in First Tracks Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including First Tracks Biotherapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in First Tracks Biotherapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $41M 2.0M 20.12

More positions owned by Affinity Asset Advisors

Roivant Sciences SHS (ROIV)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Xenon Pharmaceuticals (XENE)
Erasca (ERAS)
Alkermes SHS (ALKS)
Insmed Com Par $.01 (INSM)
Moderna Put Option (MRNA)
Praxis Precision Medicines I Com New (PRAX)
Oruka Therapeutics (ORKA)
Anaptysbio Inc Common (ANAB)
Avalo Therapeutics Com New (AVTX)
Cytokinetics Com New (CYTK)
Revolution Medicines (RVMD)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Affinity Asset Advisors

Top funds holding First Tracks Biotherapeutics

FMR
Affinity Asset Advisors
Trails Edge Capital Partners
Vanguard Capital Management
Jupiter Topco
Sanofi
Adage Capital Partners GP
Balyasny Asset Management
Geode Capital Management
Vanguard Portfolio Management
Goldman Sachs Group
Point72 Asset Management
Arrowstreet Capital, Limited Partnership
Federated Investors
Ally Bridge Group

View all funds holding First Tracks Biotherapeutics